Qiagen NV (NASDAQ:QGEN) has been upgraded to Hold in a statement by Zacks Investment Research earlier today.
- Updated: April 21, 2017
Having a price of $28.67, Qiagen NV (NASDAQ:QGEN) traded -0.03% lower on the day. With the last close up 0.37% from the two hundred day average, compared with the Standard & Poor's 500 Index which has increased 0.03% over the same period. QGEN has recorded a 50-day average of $28.89 and a two hundred day average of $28.55. Trade Volume was down over the average, with 216,532 shares of QGEN changing hands under the typical 789,873
Zacks Investment Research has upgraded Qiagen NV (NASDAQ:QGEN) to Hold in a statement released on 4/21/2017.
Recent Performance Chart
Qiagen NV has PE ratio of 81.19 with a one year low of $20.71 and a one year high of $30.25 and has a market capitalization of $0.
General Company Details For Qiagen NV (NASDAQ:QGEN)
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.